<?xml version="1.0" encoding="UTF-8"?>
<p id="Par111">They used all complete sequences of SARS-related viruses that were available at GenBank by January 1st, 2020 to create oligonucleotides and carry out in-silico evaluation. Then, they used these sequences for alignment and assay design.</p>
